首页|生长抑素联合血必净治疗急性胆囊炎及对患者肝功能血清炎症因子的影响

生长抑素联合血必净治疗急性胆囊炎及对患者肝功能血清炎症因子的影响

扫码查看
目的 研究生长抑素联合血必净治疗急性胆囊炎(AC)及对患者肝功能、血清炎症因子的影响.方法 选择2022年1~12月于河北省第七人民医院治疗的AC患者126例,依照随机数字表法分为试验组与对照组,每组63例.对照组行常规对症治疗+生长抑素治疗,试验组行常规对症治疗+生长抑素+血必净治疗.观察两组患者临床体征改变指标;治疗前、后血清超敏C-反应蛋白(Hs-CRP)、降钙素原(PCT)、肿瘤坏死因子-α(TNF-α)等炎症因子水平;丙氨酸氨基转移酶(ALT)、总胆红素(TBIL)、谷草转氨酶(AST)及前清蛋白(PA)等肝功能指标水平;不良反应及3个月内复发率情况.结果 试验组恶心呕吐消失时间、体温恢复正常时间、腹痛消失时间、饮食恢复正常时间均优于对照组(P<0.05).治疗后,试验组血清Hs-CRP、PCT、TNF-α及ALT、TBIL、AST水平均低于对照组,PA水平高于对照组,且治疗前后各指标差值差异均有统计学意义(P<0.05).试验组临床疗效优于对照组;治疗后3个月内,试验组复发率低于对照组(P<0.05).结论 生长抑素、血必净联合治疗AC可降低血清炎症因子水平,保护肝功能,促进患者康复,疗效显著,复发率低,安全可靠.
Somatostatin combined with Xuebijing in treatment of acute cholecystitis(AC) and its effect on liver function and serum inflammatory factors
Objective To study the effects of somatostatin combined with Xuebijing on acute cholecystitis(AC) and on liver function and serum inflammatory factors. Methods A total of 126 patients with AC treated in Hebei Seventh People's Hospital from January 2022 to December 2022 were selected and divided into the experimental group (n=63) and the control group (n=63) according to random number table method. The control group received conventional symptomatic treatment combined with somatostatin treatment,and the experimental group re-ceived conventional symptomatic treatment together with somatostatin combined with Xuebijing treatment. The clinical signs of the two groups were observed,including the serum levels of hypersensitive C-reactive protein (Hs-CRP),procalcitonin (PCT),tumor necrosis factor-α (TNF-α) and other inflammatory factors before and after treatment;alanine aminotransferase (ALT),total bilirubin (TBIL),aspartate aminotransferase (AST),prealbumin (PA) and other liver function indicators. The adverse reactions and recurrence rate within three months were also compared. Results The disappearance time of nausea and vomiting,temperature return to normal,abdominal pain return time and diet return to normal time in experimental group were better than those in control group (P<0.05). After treatment,the serum levels of Hs-CRP,PCT,TNF-α,ALT,TBIL and AST in the experimental group were lower than those in the control group,and the levels of PA were higher than those in the control group,and the differences of each index before and after treatment were statistically significant (P<0.05). The clinical efficacy of the experimen-tal group was better than that of the control group,and the recurrence rate of the experimental group was lower than that of the control group within three months after treatment,with statistical significance (P<0.05). Conclusion Somatostatin combined with Xuebijing in the treat-ment of AC can reduce the level of serum inflammatory factors,protect liver function and promote the recovery of patients,with significant effi-cacy,low recurrence rate,safety and reliability.

SomatostatinXuebijingAcute cholecystitisLiver functionInflammatory factors

陈立坤、董彩丽、顾春芳、杨淑红、尹玉杰、朱小静、渠兴甫

展开 >

073000 河北保定 河北省第七人民医院外四科

073000 河北保定 河北省第七人民医院检验科

073000 河北保定 河北省第七人民医院药剂科

073000 河北保定 河北省第七人民医院中医科

展开 >

生长抑素 血必净 急性胆囊炎 肝功能 炎症因子

河北省2020年度医学科学研究课题项目

20200620

2024

安徽医学
安徽省医学情报研究所

安徽医学

CSTPCD
影响因子:1.123
ISSN:1000-0399
年,卷(期):2024.45(8)